Comerica Bank lowered its holdings in Endo International PLC (NASDAQ:ENDP) (TSE:ENL) by 4.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 189,044 shares of the company’s stock after selling 9,561 shares during the period. Comerica Bank owned 0.08% of Endo International worth $662,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in the company. Oregon Public Employees Retirement Fund grew its position in shares of Endo International by 1.8% in the first quarter. Oregon Public Employees Retirement Fund now owns 77,330 shares of the company’s stock valued at $621,000 after purchasing an additional 1,397 shares during the period. Mason Street Advisors LLC grew its position in Endo International by 3.4% during the first quarter. Mason Street Advisors LLC now owns 64,141 shares of the company’s stock valued at $515,000 after acquiring an additional 2,134 shares during the period. Piedmont Investment Advisors Inc. grew its position in Endo International by 5.8% during the first quarter. Piedmont Investment Advisors Inc. now owns 50,737 shares of the company’s stock valued at $407,000 after acquiring an additional 2,795 shares during the period. Arizona State Retirement System grew its position in Endo International by 1.4% during the second quarter. Arizona State Retirement System now owns 312,262 shares of the company’s stock valued at $1,287,000 after acquiring an additional 4,167 shares during the period. Finally, Rhumbline Advisers grew its position in Endo International by 0.9% during the first quarter. Rhumbline Advisers now owns 507,253 shares of the company’s stock valued at $4,073,000 after acquiring an additional 4,547 shares during the period. 95.80% of the stock is owned by institutional investors and hedge funds.
In related news, Director Roger H. Kimmel sold 34,951 shares of the business’s stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $3.93, for a total value of $137,357.43. Following the transaction, the director now owns 148,309 shares in the company, valued at $582,854.37. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.50% of the company’s stock.
ENDP has been the subject of a number of research reports. Royal Bank of Canada reissued a “hold” rating and set a $6.00 price target on shares of Endo International in a research report on Thursday, August 8th. Citigroup downgraded Endo International from a “buy” rating to a “neutral” rating and lowered their price target for the company from $19.00 to $5.00 in a research report on Monday, June 17th. Morgan Stanley set a $2.00 price target on Endo International and gave the company a “sell” rating in a research report on Friday, August 9th. BidaskClub downgraded Endo International from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 18th. Finally, Cantor Fitzgerald reduced their price objective on Endo International from $18.00 to $4.75 and set a “neutral” rating on the stock in a research note on Wednesday, June 12th. Four investment analysts have rated the stock with a sell rating, eleven have given a hold rating and two have issued a buy rating to the company’s stock. Endo International presently has a consensus rating of “Hold” and an average price target of $7.89.
Shares of NASDAQ:ENDP traded down $0.09 during trading on Friday, hitting $3.87. The company’s stock had a trading volume of 208,107 shares, compared to its average volume of 9,744,917. Endo International PLC has a fifty-two week low of $1.97 and a fifty-two week high of $18.50. The stock’s 50-day moving average price is $2.77 and its two-hundred day moving average price is $5.64. The company has a market capitalization of $929.40 million, a PE ratio of 1.36 and a beta of 1.23.
Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings results on Monday, August 5th. The company reported $0.52 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.47 by $0.05. Endo International had a negative return on equity of 129.30% and a negative net margin of 19.98%. The business had revenue of $699.71 million for the quarter, compared to analysts’ expectations of $694.60 million. During the same quarter in the previous year, the firm posted $0.76 earnings per share. The company’s revenue was down 2.1% compared to the same quarter last year. Equities research analysts forecast that Endo International PLC will post 2.17 EPS for the current year.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Read More: What is a management fee?
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.